-
-
-
-
-
-
-
Pacira BioSciences reports $726.4 million revenue for 2025
-
-
-
-
-
-
-
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
-
-
-
-
-
-
-
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
-
-
-
-
-
-
-
Pacira BioSciences (PCRX) Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
-
-
-
-
-
-
-
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
-
-
-
-
-
-
-
Pacira BioSciences (PCRX) Confirms Receipt of Director Nominations from DOMA Perpetual
-
-
-
-
-
-
-
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

